China Protection Trial of Glucose Metabolism by Pitavastatin in Patients With Prediabetes and Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 396 participants.

Also called NCT03532620

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 396 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03532620
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03532620. Randomized; no masking; primary purpose treatment. Start 2018-08-09 (actual); primary completion 2019-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
China Protection Trial of Glucose Metabolism by Pitavastatin in Patients With Prediabetes and Hypertension
Acronym
CAMPUS
Condition
Prediabetic State
Condition
Hypertension
Condition
Dyslipidemias
Intervention (Drug)
Pitavastatin Calcium
Intervention (Drug)
Atorvastatin Calcium
Lead sponsor
Jun Tao (class: other)
Collaborator
Sun Yat-sen University (class: other)

Record details

Record id
cardio:ct-nct03532620
Content hash
19b8681bbfcafa9e01c930331484da17b446b4a236785f75b390bd5d93f4f1ee